Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 7,425 | 9,511 | 9,771 | 10,929 | 13,363 |
| Cost of Goods | 6,340 | 8,221 | 8,441 | 9,670 | 11,096 |
| Gross Profit | 1,085 | 1,290 | 1,330 | 1,259 | 2,267 |
| Operating Expenses | 4,390 | 3,084 | 4,364 | 2,220 | 1,307 |
| Operating Income | -2,965 | -1,574 | -2,594 | -291 | 1,056 |
| Interest Expense | 84 | 148 | 69 | 0 | 0 |
| Other Income | 64 | 127 | 55 | -13 | -13 |
| Pre-tax Income | -2,985 | -1,595 | -2,608 | -304 | 1,043 |
| Income Tax | N/A | 4 | 22 | 52 | 291 |
| Net Income Continuous | -2,985 | -1,598 | -2,629 | -356 | 752 |
| Net Income | $-2,985 | $-1,598 | $-2,629 | $-356 | $752 |
| EPS Basic Total Ops | -1.61 | -0.90 | -0.17 | -0.46 | 0.48 |
| EPS Basic Continuous Ops | -1.61 | -0.90 | -0.17 | -0.25 | 0.53 |
| EPS Diluted Total Ops | -1.61 | -0.90 | -0.17 | -0.46 | 0.48 |
| EPS Diluted Continuous Ops | -1.61 | -0.90 | -0.17 | -0.25 | 0.53 |
| EPS Diluted Before Non-Recurring Items | N/A | -0.09 | -1.80 | 0.00 | 0.00 |
| EBITDA(a) | $-2,713 | $-1,273 | $-2,417 | $-186 | $1,164 |